Trial for GTX-102 to Open Enrollment Soon in the UK

Trial for GTX-102 to Open Enrollment Soon in the UK

298104

Trial for GTX-102 to Open Enrollment Soon in the UK

The United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized a Phase 1/2 clinical trial to test the investigational therapy GTX-102 in children and adolescents with Angelman syndrome. The open-label KIK-AS trial (NCT04259281), which also has been given a green light in Canada, is expected to open enrollment in the U.K. soon. Clinical data from the first patients are expected before the end of the year. Enrollment for clinical sites in the U.S. is pending an amendment to the…

You must be logged in to read/download the full post.